UCBJF News and Press, Ucb Sa Npv From 02/06/23

Summary argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher went to waste. Getting subcutaneous efgartigimod to market is important as ...

Summary Immunovant is developing a similar drug to argenx, but at 10% of argenx’s valuation, offering a good option value and a hedge against owning argenx. Immunovant has a new generation anti-FcRn IMVT-1402, and recent pre-clinical data showed that it does not impact albumin le...

UCB ( OTCPK:UCBJF ) said phase 3 data from three trials on its monoclonal antibody bimekizumab indicate its effectiveness for psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. Data from one trial showed that treatment with bime...

The U.S. Food and Drug Administration approved UCB's (OTCPK:UCBJF) (OTCPK:UCBJY) Fintepla (fenfluramine) oral solution CIV to treat seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years of age and older. The FDA has also granted Fintepla pediatric exclusi...

The following slide deck was published by UCB SA in conjunction with their 2021 Q4 earnings call. For further details see: UCB SA 2021 Q4 - Results - Earnings Call Presentation

UCB SA (UCBJF) Q4 2021 Earnings Conference Call February 24, 2022, 8:00 AM ET Company Participants Jean-Christophe Tellier – Chief Executive Officer Sandrine Dufour – Chief Financial Officer Iris Löw-Friedrich – Chief Medical Officer Antje Witte – Vice Preside...

UCB SA press release (OTCPK:UCBJF): FY Non-GAAP EPS of €6.49. Revenue of €5.78B (+8.0% Y/Y). For further details see: UCB SA Non-GAAP EPS of €6.49, revenue of €5.78B

GlaxoSmithKline (GSK +1.7%) has joined a long list of pharmaceutical companies that will limit its medications purchased at prices under the federal government's 340B drug discount program to certain safety net hospital covered entities. In a letter sent Monday, GSK (GSK +1.7%) said that begi...

Zogenix (NASDAQ: ZGNX) stock is having the ride of its life this week -- perhaps for the last time in its history. The biotech announced Wednesday it agreed to be acquired by Belgium-based pharmaceutical company UCB (OTC: UCBJF) . The deal is valued at up to $1.9 billion whe...

UCB SA (UCBJF) Q2 2021 Results Conference Call July 29, 2021 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO Emmanuel Caeymaex - EVP, Head, Immunology Patient Value Unit Iris Löw-Friedrich - Chief Medical Officer Sandrine Dufour - CFO Charl Van Zyl - E...